Literature DB >> 6967667

Pharmacokinetics and metabolism of diltiazem in man.

V Rovei, R Gomeni, M Mitchard, J Larribaud, C Blatrix, J J Thebault, P L Morselli.   

Abstract

Dilitazem, a coronary vasodilating agent, after oral administration of four different doses, was well and rapidly absorbed. The pharmacokinetics of the drug followed a two-compartment model, with a rapid distribution and an elimination with a half-life of 4-7 hours. After chronic treatment the pharmacokinetic parameters were practically unchanged and therefore no accumulation of the drug was observed. The comparison between capsule and tablet preparations showed that both forms had a similar bioavailability. Diltiazem was extensively metabilized and only a few percent of the drug was found in urine. Several metabolites, also present as conjugates, have been identified by means of gas chromatography-mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967667

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  17 in total

Review 1.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly.

Authors:  A Millaire; O Leroy; P de Groote; C Santré; G Ducloux
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 3.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 4.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

Review 5.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

6.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

Authors:  S C Montamat; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

7.  Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

Authors:  G Caillé; S Boucher; J Spénard; Z Lakhani; A Russell; J Thiffault; M G Grace
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 8.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 10.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.